ERAS-0015
Small molecule
Also known as JYP0015
Evidence outlook
Non-Small Cell Lung Cancer: mid-stage studies underway, no completed readout
In Non-Small Cell Lung Cancer, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Also in development:Pancreatic Ductal Adenocarcinoma · Phase 2
Company guidance: topline data expected later this year (Erasca, 11 Aug 2026). “Our recent financing should position us to accelerate ERAS-0015 toward three potentially registration-enabling trials while maintaining momentum across our broader pipeline, including the upcoming ERAS-4001 clinical data readout expected later this year.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STAR NCT06895031 · Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Registry: NCT06895031 | 2 | Number of Participants with Dose-Limiting Toxicity (DLT) (21 days); Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEs (Up to 3 years); Overall Response Rate (ORR) (Up to 3 years) 2026-03-30 | In progress: primary completion was expected 30 Mar 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other pan-RAS drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ERAS-0015: this drug | Phase 2 | Small molecule | pan-RAS | not yet graded | No reviewed efficacy summary in this indication | |
| Daraxonrasib (Rasonque) | Approved | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| INCB161734 | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Quemliclustat | Phase 3 | Small molecule | CD73 (NT5E) | not yet graded | No reviewed efficacy summary in this indication | |
| Setidegrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Tambotatug Pelitecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Navlimetostat | Phase 2/3 | Small molecule | PRMT5 (protein arginine methyltransferase 5), MTA-cooperative binding | not yet graded | No reviewed efficacy summary in this indication | |
| Autogene Cevumeran | Phase 2 | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| GFH375 | Phase 2 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Nuzefatide Pevedotin | Phase 2 | Peptide | EphA2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARV-806 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Vopimetostat | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ERAS-0015 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent